DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Sulfated CCR5 Peptides For HIV-1 Infection

the specification (check one)	oj wnich:			
	X is	ossached hereto.		·
•	wa	s filed on		as
	Application	serial No		
٠.	and was an	nended		
			(if ap	plicable)
I hereby state the including the clai	ns I have reviewed ims, as amended by	and understand the contents of any amendment referred to abo	the above-iden	tified specification,
l acknowledge the to be material to p	duty to disclose to patentability as def	the U.S. Patent and Trademark (ined in Title 37, Code of Federa	Office all informal Regulations. S	nation known to me Section 1.56.
to be material to p Thereby claim fore 365(b) of any for International App below. I have alst International Appli	patentability as def ign priority benefits eign application(s, lication which des a identified below i	the U.S. Patent and Trademark (ined in Title 37, Code of Federal under Title 35, United States Color patent or inventor's certificing ignated at least one country of any foreign application for pateing date before that of the earliest	d Regulations. S ode, Section 1 I cate, or Section ther than the U nt or inventor's	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT
to be material to p thereby claim fore 365(b) of any for International App below. I have also International Appli is claimed:	patentability as defign priority benefits eign application(s, lication which deso identified below to ication having a fil	ined in Title 37. Code of Federa under Title 35. United States Co for patent or inventor's certific ignated at least one country of any foreign application for pate	l Regulations, S ode, Section I I cate, or Section ther than the U nt or inventor's est application	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT
to be material to p thereby claim fore 365(b) of any for International App below. I have also International Appli is claimed:	patentability as defign priority benefits eign application(s, lication which deso identified below to ication having a fil	ined in Title 37. Code of Federa under Title 35. United States Co for patent or inventor's certific ignated at least one country of any foreign application for pate	l Regulations, S ode, Section I I cate, or Section ther than the U nt or inventor's est application	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT from which priority
to be material to p thereby claim fore 365(b) of any for International App below. I have also International Appli is claimed: Prior Foreign App	patentability as defign priority benefits eign application(s) lication which deso identified below (scation having a fill lication(s)	ined in Title 37. Code of Federa under Title 35. United States Co for patent or inventor's certific ignated at least one country of any foreign application for pate ing date before that of the earlie	d Regulations, S ode, Section 11 case, or Section ther than the U nt or inventor's est application	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT from which priority ty Claimed
to be material to p thereby claim fore 365(b) of any for International App below. I have also International Appli is claimed: Prior Foreign App	patentability as defign priority benefits eign application(s) lication which deso identified below (scation having a fill lication(s)	ined in Title 37. Code of Federa under Title 35. United States Co for patent or inventor's certific ignated at least one country of any foreign application for pate ing date before that of the earlie	d Regulations, S ode, Section 11 case, or Section ther than the U nt or inventor's est application	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT from which priority ty Claimed
to be material to p thereby claim fore 365(b) of any for International App below. I have also International Appli is claimed: Prior Foreign App	patentability as defign priority benefits eign application(s) lication which deso identified below (scation having a fill lication(s)	ined in Title 37. Code of Federa under Title 35. United States Co for patent or inventor's certific ignated at least one country of any foreign application for pate ing date before that of the earlie	d Regulations, S ode, Section 11 case, or Section ther than the U nt or inventor's est application	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT from which priority ty Claimed
to be material to p I hereby claim fore 365(b) of any for International App below. I have also International Appli is claimed: Prior Foreign App Number	patentability as defign priority benefits eign application(s) lication which deso identified below (scation having a fill lication(s)	ined in Title 37. Code of Federa under Title 35. United States Co for patent or inventor's certific ignated at least one country of any foreign application for pate ing date before that of the earlie	d Regulations, S ode, Section 11 case, or Section ther than the U nt or inventor's est application	Section 1.56. 9 (a)-(d) or Section 365(a) of any PCT Inited States, listed certificate, or PCT from which priority ty Claimed

I hereby claim the benefit under Title 35. United States Code. Section 119(e) of any United States provisional application(s) listed below:

Provisional Application No.	Filing Date	<u>Sianis</u>
60/272,203	February 28, 2001	pending
N. J. J. J. J. Lander and	Title 25 United State Code	Section 120 of any thread Sec

I hereby claim the benefit under Title 35. United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35. United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s), and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Stohus
N/A		···
	· ·	

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. No.38,232); Paul Teng (Reg. No. 40,837); Richard F. Jaworski (Reg. No. 33,515); Alan J. Morrison (Reg. No. 37,399); Mark A. Farley (Reg. No. 33,170); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Alan D. Miller (Reg. No. 42,889); and Frank Bruno (Reg. No. 46,583)

and each of them, all c/o Cooper & Dunham LLP. 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Declaration and	Power of Attorney			Page 3
Please address a	all communications, an	d direct all telephone	e calls.	regarding this application to:
John 1	P. White	Re	e No	28,678
1185 Ave New York	& Dunham LLP enue of the Americas k, New York 10036 t) 278-0400		s v. –	
made on informati the knowledge that or both, under Se	ion and belief are believ I willful false statement	ved to be true: and fu is and the like so mad of the United States	riher il de are j Code a	edge are true and that all statement hat these statements were made wi punishable by fine or imprisonmen and that such wiilful false statement thereon.
Full name of sole first joint inventor	or Tatjana Dra	agic		
Inventor's signatu	re			
Citizenship		Date of sign	atur e _	
				33
•				
Full name of joint				
inventor (if any)	William C. C	•		
Inventor's signature				
CitizenshipU.	S.A.	Date of sign	ature_	
Residence 21	Fawn Court, Ossi	ining, NY 10562		
	same as above			•
, 02. 03,				
-				
Full name of joint inventor (if any)				
Inventor's signature				
Citizenship		Date of sign	ature_	
Residence				
Post Office Address_	· · · · · · · · · · · · · · · · · · ·		• .	

Applicant or Patentee. Tatjana. Dragic and William C. Olso Serial or Patent No.: Not Yet Known	n Actorney's Docket No.:61010-AB-1/J
riled or Issued: Title of Invention or Patent: Sulfated CCR5 Peptides for	HIV-1 Infection
ACCIDIO CANDADAM (DEVIADAMICAL) CIA YI	447 5
VERIFIED STATEMENT (DECLARATION) CLAIN SMALL ENTITY STATUS UNDER 37 C.F.R. Sl.	
AND \$1.27(d) - SMALL BUSINESS CONCER	RN
I hereby declare that I am:	*.
the owner of the small business concern identifie	ed below.
X an official of the small business concern empowered concern identified below:	d to act on behalf of the
Name of Concern: Progenics Pharmaceuticals, Inc.	• • • •
Address of Concern: 777 Old Saw Mill River Road	
Tarrytown, New York 10591	
that the number of employees of the concern, including those on the exceed five hundred (500) persons. For purposes of this we number of employees of the business concern is the average number of employees of the business concern is the average number of employees of the persons employed by the business compart-time, or temporary basis during each-pay period of concerns are affiliates of each other when, either direct concern controls or has power to control the other, or a trend or has power to control the other, or a trend or has power to control both. I hereby declare that rights under contract or law have been with the small business concern identified above with regentitled	rerified statement, the mber, over the previous occurs on a full-rime, the fiscal year, and ly or indirectly, one third party or parties conveyed to and remain
Sulfated CCR5 Peptides for HIV-1 Infection	
described in:	
I the specification filed herewith	
application serial no. filed patent no. issued	
If the rights held by the above identified small business concern individual, concern or organization having rights to the below and no rights to the invention are held by any per inventor, who could not qualify as an independent inventor under any concern which could not qualify as a small business C.F.R. \$1.9(d)* or as a nonprofit organization under 37 C.F.E.	ern are not exclusive, a invention is listed rson, other than the er 37 C.F.R. \$1.9(c)*, as concern under 37
Name: N/A	
Add168:	
Individual Small Business Concern Nonprof	it Organization
	Aurren gebeurt Gr

*NOTE: Separate verified statements are required for each named person, concern, or organization having rights to the invention averxing to their status as small

Serial No.: Not Yet Known Filed:

Small Entity/Small Business Concern
Page -2-

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. \$1.28(b)*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing:	Paul M. Maddon M.D., Ph.D.
Title In Organization:	Chairman & CEO, Scientific Director
Address:	777 Old Sau Mill Road
	Tarrytown, New York 10591
Signature: au /	Maddon
Signature: and pate of Signature: 2/2	6/07